GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 86.96B +44.7% |
| Revenue (ttm) | 32.67B +4.1% |
| Net Income | 5.72B +122.0% |
| EPS | 1.39 +123.2% |
| Shares Out | 4.00B |
| PE Ratio | 15.68 |
| Forward PE | 12.03 |
| Dividend | 0.72 (3.31%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 8,127,573 |
| Average Volume | 8,610,682 |
| Open | 2,156.00 |
| Previous Close | 2,167.00 |
| Day's Range | 2,156.00 - 2,196.00 |
| 52-Week Range | 1,263.50 - 2,282.00 |
| Beta | 0.35 |
| RSI | 64.68 |
| Earnings Date | Apr 29, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial StatementsNews
GSK sees blockbuster potential in targeted cancer therapy after promising early data
British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped shrink tumors in ...
GSK withdrew an application of a drug touted by Trump and RFK Jr. as a potential treatment for autism. The drug's label last month was updated so that generic versions of it can be marketed for a rare genetic, neurological condition, but not autism.
Generic versions of the drug will still be available to treat a rare genetic condition.
Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expandi...
US FDA approves GSK's drug for liver disease related itching
The U.S. Food and Drug Administration approved GSK's drug for severe relentless itching caused by a type of liver disease, the company said on Thursday, making it the first treatment greenl...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
GSK and Amgen to add medicines to TrumpRx, Fox Business reports
GSK and Amgen will add their medicines to TrumpRX, the prescription drug website launched by President Donald Trump's administration, Fox Business reported on Friday.
GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
PHILADELPHIA--(BUSINESS WIRE)--GSK's RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk.
GSK gets US FDA approval for expanded use of RSV vaccine
British drugmaker GSK said on Friday the U.S. Food and Drug Administration has expanded the approved age range for its respiratory syncytial virus vaccine, Arexvy, to include adults aged 18 to 49 wh...
FDA Approves Drug Trump Touted for Autism to Treat Other Neurological Disorder
The Food and Drug Administration approved leucovorin, a drug the Trump administration has touted as a potential therapy for autism, to treat cerebral folate transport deficiency, a neurological disord...
FDA Approves Leucovorin—But Not For Autism, Even After Trump Admin Officials Touted Drug Last Year
The Food and Drug Administration approved the drug leucovorin as a treatment for the rare genetic condition cerebral folate deficiency on Tuesday—but stopped short of approving it as a treatment for ...
US FDA approves leucovorin for ultra- rare genetic disorder causing autism-like symptoms
WASHINGTON, March 10 (Reuters) - The U.S. FDA on Tuesday approved leucovorin, a decades-old generic drug, for use against an ultra-rare disorder called cerebral folate deficiency, but not for childre...
FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment
The Food and Drug Administration approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children.
GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million
Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat.
GSK licenses liver disease drug to Italy's Alfasigma
GSK has agreed to sell its worldwide rights to develop and commercialise its experimental liver disease drug linerixibat to Italian pharmaceutical company Alfasigma for an upfront payment o...
GSK to Buy 35Pharma for $950 Million
GSK struck a deal to buy Canada's 35Pharma as the U.K. drugmaker seeks to bolster its exposure to diseases linked to obesity.
GSK to buy 35Pharma for $950 million
GSK on Wednesday agreed to buy Canadian biopharmaceutical company 35Pharma Inc for $950 million in cash.
35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announc...
Frontier Biotechnologies strikes up to $1 billion deal with GSK
Frontier Biotechnologies said on Tuesday it has struck a deal with GSK , granting the British drugmaker worldwide rights to develop two small interfering RNA therapies targeting kidney diseases in an ...
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract.
GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
PHILADELPHIA--(BUSINESS WIRE)--GSK's AREXVY associated with reductions in certain RSV-related risks, real world study shows.
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT ...
3 International Stocks to Buy for 2026
Plus, which countries and sectors look most attractive to invest in today. In this bonus episode of The Morning Filter podcast, host Susan Dziubinski talks with Morningstar chief Europe markets strate...
GSK's Specialty Medicines Drive Solid Results
The pharma company posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for 2025, with sales of £32.67 billion.
GSK forecasts slower sales growth in 2026
GSK on Wednesday forecast sales growth to slow in 2026 in the first outlook presented by new CEO Luke Miels as the drugmaker shifts focus on expanding its pipeline to counter looming patent expiries f...